dr. katz on redefining risk assessment in prostate cancer with 17-gene oncotype dx gps
Published 4 years ago • 518 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
2:25
dr. katz on the oncotype dx gps assay in prostate cancer
-
1:22
dr. katz on redefining risk stratification in prostate cancer
-
0:58
dr. katz on determining low-risk disease in prostate cancer
-
1:51
assay shows value for patients with low-risk prostate cancer
-
27:03
segment 2: risk assessment in prostate cancer
-
11:27
prostate cancer and gleason score or group video
-
6:26
treatment strategies for gleason 3 4=7 vs. 4 3=7 | ask a prostate cancer expert, mark scholz, md
-
7:52
does high psa levels = prostate cancer? | dr steven tucker
-
17:45
point-counterpoint: oncotype dx genomic prostate score in active surveillance – canary pass study
-
5:37
prostate cancer grading and risk assessment
-
4:18
the use of cthpvdna as a predictor of cancer recurrence and an indicator for dart
-
2:04
unmet need in bladder cancer
-
1:49
test for breast cancer patients to detect the risk of recurrence
-
0:48
diagnostic testing for prostate cancer
-
1:47
current and upcoming clinical trials in bladder cancer
-
4:31
clinical implications of ctcs in prostate cancer – are they the best thing to measure?
-
1:25
potential of ctcs for biomarker detection in prostate cancer
-
9:54
adt and cardiovascular risk in prostate cancer: q&a
-
1:02
risk factors with bladder cancer
-
2:02
pcss - prostate cancer test differences
-
1:31
focusing on you: improvements in bladder cancer detection
-
1:33
hot topics in bladder cancer from asco gu 2023